

ALPHA-L-FUCOSIDASE AS A PUTATIVE PROGNOSTIC BIOMARKER IN BREAST CANCER

Z. M. A. A. HAMODAT^{1✉}, H. H. ABDULWAHHAB², A. R. M. T. HAMODAT³

¹Department of Chemistry, College of Science, University of Mosul, Iraq;

²Northern Technical University, AL-dour, Iraq;

³Mosul Center for Cardiac Medicine and Surgery, Mosul, Iraq;

✉ e-mail: zahraahamodat@uomosul.edu.iq

Received: 05 January 2024; **Revised:** 03 February 2024; **Accepted:** 31 May 2024

Search for reliable biomarkers for predicting progression of breast cancer is essential in managing the disease. So, we are trying to provide new insights into the potential role of alpha-fucosidase (AFU) as a putative prognostic biomarker in breast cancer as compared to classic markers. The study included 56 women with breast cancer; 25 had early breast cancer, and the rest (31) had metastatic breast cancer. Thirty healthy women were considered a control group. Early breast cancer patients had a significantly increased ($P \leq 0.0001$) AFU level compared with the control group. A non-significant difference in the De-rititis ratio appeared for early breast cancer compared with control. Metastatic breast cancer had a significantly ($P \leq 0.0001$) increased AFU and De-rititis ratio compared with early breast cancer and the control group. A positive significant ($P = 0.01$) correlation exists between AFU level, age factor ($r = 0.295$), and the De-rititis ratio in breast cancer patients. We can conclude that it is possible to consider alpha-L-fucosidase (AFU) as a putative prognostic biomarker in breast cancer more potent than the ratio of De-Ritis. Moreover, the co-incidence of elevated AFU and De-rititis levels in metastatic breast cancer gives us an idea of the stage of the disease.

Key words: alpha-L-fucosidase, the De-rititis ratio, early breast cancer, metastasis.

The most prevalent malignancy diagnosed is breast cancer [1, 2] and the second leading cause of cancer mortality in females worldwide. It is a varied and heterogeneous disease with various symptoms, prognoses, and therapeutic responses [2].

The most frequent type of cancer in women globally is cancer of the breast [1]. Over 250,000 new cases were identified in 2017, indicating a lifetime incidence of 12% in women in the United States [3]. In the United States, over half of all breast cancer diagnoses are given to women over the age of 60. By 2040, the global burden of cancer will have increased by half compared to 2020 [4]. Furthermore, among Iraqi women, breast cancer ranks highest in incidence and mortality [5, 6]. The number of instances of breast cancer in Iraq rose from 26.6 per 100,000 in 2000 to 31.5 per 100,000 in 2009. The number of cases of breast cancer in Iraq rose from 26.6 per 100,000 in 2000 to 31.5 per 100,000 in 2009 [5, 7]. Iraq also has a higher age-related incidence rate than Iran, Bahrain, Saudi Arabia, and Turkey but lower

rates than Kuwait and Jordan. Iraq also has a higher age-related incidence rate than Iran, Bahrain, Saudi Arabia, and Turkey but lower rates than Kuwait and Jordan [5]. In 2019, breast cancer ranked first in both incidence rate (35.95 per 100,000 people) and percentage of cancer cases; it also had the highest mortality rate (22.58 per 100,000 people) and incidence rate (34.08%) [8]. Metastasis is the leading cause of death among cancer patients. Circulating tumour cells must overcome numerous hurdles to infiltrate distant tissues. These include penetrating foreign tissue, avoiding immune defenses, adapting to supportive niches, living as dormant tumor-initiating seeds, and eventually erupting to replace the host tissue [9]. Breast cancer metastasis is still increasing in frequency. Cancer diagnostics can benefit from fucose related to tumor formation, lymphomagenesis, and vascular attack [10-12]. Many fucosylated glycans are degraded by alpha-L-fucosidase, which has long been known as a tumor marker linked to early diagnosis of H.C.C. as well as colon cancer [13-19]. Alpha-L-fucosidase (EC 3.2.1.51; AFU) is a lysoso-

mal enzyme. It removes terminal L-fucose residues from glycoconjugate oligosaccharide chains [17-25]. The AFU has been linked to the breakdown and disruption of alpha fucose levels in mammalian cells. As a result, an abnormality in the level of fucose isn't just related to an increase in the deformation of fucoglycans, such as glycoproteins, lipid molecules, and mucopolysaccharides found on the cell surface, but it is also linked to an alteration in the survival of cells. Cancer diagnostics can benefit from fucose related to tumor formation, lymphomagenesis, and vascular attack [10-12]. Because of the importance of AFU, the activity of Alpha-L-fucosidase has been investigated in a variety of sources [16, 21, 26-34].

The De-rititis ratio was first reported in 1957 by De-rititis and Gusi. Therefore, it has since been known as the De-rititis ratio [35]. De-rititis ratio represents the ratio of serum aspartate aminotransaminase (AST) to alanine aminotransaminase (ALT) [36, 37]. De-rititis ratio was used as a biomarker to predict viral hepatitis, but it is now used as a prognostic marker in many diseases, including hepatic cell carcinoma. (HCC) [38], breast carcinoma [39], renal cell carcinoma [40], testicular tumor [41], and urothelial carcinoma [42]. In some solid tumours, an elevated De-rititis ratio has been a poor diagnostic indicator [36, 42-44]. In prostate, renal, and urothelial carcinoma, a high De-rititis ratio has been reported to be a poor prognostic predictor [44]. A high De-rititis ratio has also been linked to a poor prognosis in other solid tumours, such as breast and lung cancer [36, 44].

In this study, we aimed to answer the following questions: 1 – Do metastasis breast cancer patients have a higher L-fucosidase and De-rititis than early breast cancer? 2 – Do patients correlate with the level activity of AFU and the level of De-rititis ratio (aspartate transaminase (AST)/alanine transaminase (ALT) ratio)?

Materials and Methods

Population study. The study was conducted on 56 patients with breast cancer aged (30-65) years. They attended the outpatient clinics of Al-Oram Teaching Hospital and the clinic for cancer disease licensed by the Ministry of Health in Mosul, Iraq. They were between December 15, 2020, and June 25, 2021. All patients diagnosed by specialists underwent a physical and clinical examination of the disease. In this study, patients with any other malignant tumours were excluded.

Also, 30 healthy women represented the control group, i.e. women with a healthy condition and without cancer. And their ages ranged from 30 to 65 years.

Experimental design. The selected samples were distributed into four groups as follows. The first group, 30 (Group 1), the second group, 56 (Group 2), included the total patients with breast cancer. The third group, 25 (Group 3), included women with breast cancer (the presence of a mass inside the breast) who had an early (initial) stage of progression of the disease. It was noted that there was swelling (swelling) of the glands under the armpit, with pain in the axillary area before treatment (some had it removed. They have new lumps. The fourth group 31 (Group 3) represented the metastatic breast cancer group in infection, as the disease was transmitted–metastasis to other organs, including the liver, lung, bone and spine.

All participants were given an informed consent questionnaire form to participate in the research. The study was carried out under the study protocol established by the Ethics Committee of the University of Mosul's College of Science and the Health Department in Nineveh (Protocol No. 20/153 on 23/12/2020).

Sample collection. Serum The AFU level was measured four weeks before the procedure. Patients fasted, venous blood samples were taken, and serum was extracted by centrifuge [12, 45].

Five millilitres of Fasting venous blood samples were collected from adults. After coagulation for 20 min at 37°C, it was centrifuged at 3000 g for 20 min. Serum was collected and stored at -20°C [12].

Serum samples were collected from patients with early breast cancer before surgical removal of the primary tumour, with no neoadjuvant treatment or indication of metastasis.

The serum samples for the metastatic breast cancer patients were obtained after at least one confirmed metastasis, with a median period of 12 months from about the date of the first metastasis.

Assay of α -L-fucosidase level. The sandwich-ELISA method was employed to assay the level of α -L-fucosidase. by using of the E-EL-H0290 Human FUCA (alpha-L-fucosidase, Tissue) ELISA Kit from Elabscience. It is also known as FUCA1, A-FU, or aFU. The manufacturer's instructions were followed when the test was conducted, and the idea of the test was incorporated. This kit's micro ELISA plate al-

ready has a human FUCA-specific antibody. Before combining the sample or standard with the appropriate antibody, they add it to the wells of the micro ELISA plate. A biotinylated detection antibody specific to human FUCA is applied to each well of the microplate, followed by an Avidin-Horseradish Peroxidase (HRP) conjugate, and the plates are then incubated. Dissolved components are removed by washing. Every well is then filled with the substrate solution. A blue colour will be produced only in the wells that contain the Human FUCA, biotinylated detection antibody, and Avidin-HRP conjugate. The hue changes to yellow when the enzyme-substrate reaction is stopped by adding the stop solution. At a wavelength of 450 ± 2 nm, the spectrophotometric measurement of the optical density (OD) is taken. The concentration of Human FUCA is directly related to the OD value. By comparing the samples' optical density (OD) with the standard curve, you may determine the concentration of human FUCA in the samples. Before testing, a one-to-five ratio was used to dilute all samples in a diluted solution.

Assay the level of De-ritis ratio (AST/ALT ratio). According to the manufacturer's instructions, each AST and ALT was measured using the Japanese-origin Fuji self-analysis device [46]. Then, the De-ritis ratio (AST/ALT ratio) was calculated by dividing the AST result by the ALT result [47].

Statistical analysis. The analysis was carried out using SPSS version 25. They examined the data. After obtaining the mean $\pm$ standard deviation (SD), an independent T-test was used to compare the two groups. Pearson's correlation coefficient was used to express the results of the correlation investigation. The *P*-value lower than 0.05 was considered statistically significant [48, 49]

Results and Discussion

Effect of the age factor on breast cancer. Table 1 shows the mean $\pm$ SD of the age of breast cancer patients. Each breast cancer case has a matched age (58.6 ± 10 years) and controls (54.6 ± 11 years). Therefore, there is not a significant ($P = 0.897$). Also, there are non-significant differences ($P = 0.06$) between patients with early-stage breast cancer (50.1 ± 6.2 years) and control (54.6 ± 11 years). At the same time, there is a significant difference ($P \leq 0.0001$) appeared for age of patients with metastatic breast cancer (65.9 ± 5.8 years) when compared with each of the control group (54.6 ± 12.8 years) and early-stage breast cancer group (50.1 ± 6.2

years). These results mean that risk of breast cancer progression increases with advanced age [4, 50].

Level of alpha-L-fucosidase (AFU) in patients with breast cancer. Table 2 show the level of AFU in breast cancer patients. Significantly elevated AFU levels in the serum of breast cancer patients (22.7 ± 9.8 ng/ml; $P \leq 0.0001$) compared with the healthy control group (6.3 ± 2.6 ng/ml). A significant increase ($P \leq 0.05$) in the level of AFU in early breast cancer (11.9 ± 3.6 ng/ml) compared with the healthy controls (6.3 ± 2.6 ng/ml). The level of AFU is significantly increased ($P \leq 0.001$) for metastatic breast cancer (33.6 ± 5 ng/ml) when compared with both early breast cancer (11.9 ± 3.6 ng/ml) and the healthy group (6.3 ± 2.6 ng/ml). These results indicate an increasing AFU level with tumor progression. Several studies have found that alpha-L-fucosidase activity is increased in cancer patients. They note that the level of AFU can be used for prognosis of the course of the disease and its outcome [11, 12, 30, 51]. The cause of the rise in alpha-L-fucosidase remains unknown. One probable explanation is that the tumor produces more proteins, which increases fucose metabolism [14]. Increased fucose or fucosylation content and aberrant fucosylation on the surface of the membrane of tumor cells may be attributed to tumor distant metastasis capacity. Also, it could assist abnormal cells in escaping immunological recognition [30, 45, 52, 53].

Level of De-ritis ratio (AST/ALT ratio) in breast cancer patients. The results in Table 3 showed breast cancer patients' De-ritis ratio (AST/ALT ratio) level. Significant increase in the rate of De-ritis for breast cancer patients (1.5 ± 0.7 ; $P \leq 0.0001$) compared with the healthy control group (0.68 ± 0.15). In contrast, there was no significant difference ($P = 0.06$) in the level of De-ritis for early breast cancer (0.84 ± 0.37) compared with healthy controls (0.68 ± 0.15). However, there was a significant increase ($P \leq 0.0001$) in the De-ritis ratio for patients with metastatic breast cancer (2 ± 0.32) when compared with early breast cancer patients (0.84 ± 0.37) and healthy subjects (0.68 ± 0.15). According to our findings, the ratio of De-ritis can be considered an independent prognostic factor for breast cancer progression. Several studies have indicated that the rate of De-ritis is an important prognostic indicator for many types of cancer [36, 38, 40-42, 44, 54].

The elevated AST/ALT ratio in cancer patients is still a mystery. The "Warburg effect" has revealed that most cancer cells use anaerobic glycolysis to

Table 1. Age of patients with metastatic and early stage breast cancer

Cases	n	Age (years), mean $\pm$ SD	P-Value
Control group	30	54.6 $\pm$ 11.0	0.897
Breast cancer	56	58.6 $\pm$ 10.0	0.897
Control group	30	54.7 $\pm$ 11.0	0.06
Early stage breast cancer	25	50.1 $\pm$ 6.2	0.06
Control group	30	54.6 $\pm$ 11.0	0.0001
Metastatic breast cancer	31	65.9 $\pm$ 5.8***	0.0001
Early stage breast cancer	25	49.7 $\pm$ 6.2	0.000
Metastatic breast cancer	31	65.9 $\pm$ 5.8	0.000

Note. *** refer to the P-value higher a significant at $P \leq 0.0001$

Table 2. Level of alpha-L-fucosidase (AFU) in patients with breast cancer

Cases	n	AFU (ng/ml), mean $\pm$ SD	P-Value
Control group	30	6.3 $\pm$ 2.6	0.0001
Breast cancer	56	23.9 $\pm$ 11.5***	0.0001
Control group	30	6.3 $\pm$ 2.6	0.041
Early stage breast cancer	25	11.9 $\pm$ 3.6*	0.041
Control group	30	6.3 $\pm$ 2.6	0.0001
Metastatic breast cancer	31	33.6 $\pm$ 5***	0.0001
Early stage breast cancer	25	11.9 $\pm$.4	0.0001
Metastatic breast cancer	31	33.6 $\pm$ 5***	0.0001

Note. *Refer to the P-value a significant at $P \leq 0.05$; ***refer to the P-value a higher significant at $P \leq 0.0001$

Table 3. Level of the De-ritis ratio (AST/ALT ratio) in breast cancer patients

Cases	n	AST/ALT, mean $\pm$ SD	P-Value
Control group	30	0.68 $\pm$ 0.15	0.0001
Breast cancer	56	1.5 $\pm$ 0.7***	0.0001
Control group	30	0.68 $\pm$ 0.17248	0.06
Early stage breast cancer	25	0.84 $\pm$ 0.37	0.06
Control group	30	0.68 $\pm$ 0.15	0.0001
Metastatic breast cancer	31	2.00 $\pm$ 0.32***	0.0001
Early stage breast cancer	25	0.84 $\pm$ 0.37	0.0001
Metastatic breast cancer	31	2.0 $\pm$ 0.32***	0.0001

Note. *Refer to the P-value a significance at $P \leq 0.05$; ***: refer to the P-value a higher significant at $P \leq 0.0001$. AST – alanine aspartate transaminase; ALT – alanine transferase

generate the energy needed for cellular growth, survival, as well as metastases, even in the presence of oxygen [55-57]. AST and ALT enzymes are related to glutamine metabolism, which is essential for cancer cells to produce nucleotides and nonessential amino

acids [58-60]. The enzymes AST and ALT, which represent tumour metabolism, serve as biomarkers to predict patient prognosis [42, 54, 61]. The elevated AST/ALT ratio in cancer patients is still a mystery. The “Warburg effect” has revealed that most cancer

Table 4. Correlation of AFU level with the De-ritis ratio in breast cancer patients

Parametrs	Groups		
	Total patients BC	Early stage BC	Metastatic BC
<i>AFU, ng/ml</i>			
Pearson correlation	0.89**	0.79**	0.89**
P-value	0.01	0.01	0.01
n	56	31	25
<i>De-ritis ratio</i>			
Pearson correlation	0.96**	0.32	0.83**
P-value	0.01	0.01	0.114
n	56	31	25

Note. **Refer to the P-value a higher significance of a correlation at $P \leq 0.01$; BC – breast cancer; AFU – alpha-L-fucosidase

Table 5. The area for the variable studies in breast cancer using receiver operating characteristic (ROC) curve analysis

Test result variable(s)	Groups		
	Total patients BC	Early stage BC	Metastatic BC
AFU, ng/ml	1.000	0.492	1.000
De-ritis ratio	0.872	0.360	0.991
Age, years	0.602	0.182	0.885

cells use anaerobic glycolysis to generate the energy needed for cellular growth, survival, and metastases, even in oxygen [55-57]. AST and ALT enzymes are related to glutamine metabolism, essential for cancer cells to produce nucleotides and nonessential amino acids [58-60]. Therefore, AST and ALT, representing tumour metabolism, act as biomarkers to predict disease prognosis [42, 54, 61].

Correlation of AFU level with De-ritis ratio in breast cancer patients. The results in Table 4 revealed a positive significant correlation ($P = 0.01$) for AFU level with each age for all patients with breast cancer ($r = 0.88$), early-stage breast cancer ($r = 0.79$) and metastatic breast cancer ($r = 0.89$). Also, the results in Table 4 revealed a positive significant correlation ($P = 0.01$) for AFU level with each and the De-ritis ratio for all patients with breast cancer ($r = 0.96$) and metastatic breast cancer ($r = 0.83$). At the same time, there is a non-significant correlation at early-stage breast cancer ($r = 0.32$) for AFU level with the De-ritis ratio.

The reason for appearing a significant correlation between AFU and age in all stages of breast cancer may be that breast cancer disease is a pro-

gression with advanced age [4, 50]. The age factor also has an impact on the level of AFU.

Also, the significant positive correlation between AFU activity and the De-ritis ratio may be due to an increase in the enzyme activity associated with the disease's progress, especially in the case of metastatic breast cancer. In metastatic cancer, the tumour cells need glycolysis to produce more energy [55-57].

Conclusion. We can conclude that it is possible to consider alpha-L-fucosidase a tumor marker in the early diagnosis of breast cancer more than the De-ritis ratio. Moreover, the coincidence of elevated AFU and De-Ritis levels in metastatic breast cancer gives us an idea of the stage of the disease.

Age is one of the most critical factors that can increase breast cancer risk. A significant positive correlation between the level of AFU activity and increased age may be because most patients with metastatic breast cancer are about years older than those with early breast cancer.

Also, the significant positive correlation between AFU activity and the De-ritis ratio may be due to an increase in the enzyme activity associated

with the disease's progress, especially in the case of metastatic breast cancer. In metastatic cancer, the tumor cells need glycolysis to produce more energy. Also, the alpha-L-fucosidase may be a good tumor marker for diagnosing breast cancer, especially in the metastasis stage, with and combined assay with the De-ritis ratio and the age factor. Moreover, ROC analysis shows that the alpha-L-fucosidase may be considered a promising tumor marker for diagnosing breast cancer, especially in the metastasis stage, with and combined assay with the De-ritis ratio and the age factor.

Conflict of interest. Authors have completed the Unified Conflicts of Interest form at http://ukr-biochemjournal.org/wp-content/uploads/2018/12/coi_disclosure.pdf and declare no conflict of interest.

Funding. This study did not receive external funding.

АЛЬФА-Л-ФУКОЗИДАЗА ЯК ПЕРЕДБАЧУВАНИЙ ПРОГНОСТИЧНИЙ БІОМАРКЕР ПРИ РАКУ МОЛОЧНОЇ ЗАЛОЗИ

Z. M. A. A. Hamodat¹✉, H. H. Abdulwahhab²,
A. R. M. T. Hamodat³

¹Department of Chemistry, College
of Science, University of Mosul, Iraq;

²Northern Technical University, AL-dour, Iraq;

³Mosul Center for Cardiac Medicine
and Surgery, Mosul, Iraq;

✉e-mail: zahraahamodat@uomosul.edu.iq

Пошук надійних біомаркерів для прогнозування перебігу раку молочної залози має важливе значення для лікування захворювання. Метою дослідження було оцінити потенційну роль альфа-фукозидази (AFU) як передбачуваного прогностичного біомаркера розвитку раку молочної залози порівняно з класичними маркерами. У дослідженні взяли участь 30 здорових жінок (контрольна група) і 56 жінок з раком молочної залози, серед яких 25 пацієнток мали ранній і 31 – метастатичний рак молочної залози. Показано, що у пацієнток із ранніми стадіями раку молочної залози рівень AFU був суттєво підвищений, а коефіцієнт Де Рітіса достовірно не відрізнявся від контрольної групи. Пацієнтки з метастатичним раком молочної залози мали достовірно підвищені значення як AFU, так і коефіцієнта Де Рітіса порівняно з пацієнтками

з ранньою стадією раку молочної залози та контрольною групою. Встановлена позитивна достовірна кореляція між рівнем AFU, віковим фактором ($r = 0,295$) та коефіцієнтом Де Рітіса у пацієнток із раком молочної залози. Зроблено висновок, що α -L-фукозидазу можна вважати передбачуваним прогностичним біомаркером, більш вагомим порівняно з коефіцієнтом Де Рітіса при раку молочної залози. До того ж наявність підвищених рівнів AFU та коефіцієнта Де Рітіса дає нам певне уявлення про стадію захворювання.

Ключові слова: альфа-L-фукозидаза, коефіцієнт Де Рітіса, ранній рак молочної залози, метастази.

References

1. Goff SL, Danforth DN. The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer. *Clin Breast Cancer*. 2021; 21(1): e63-e73.
2. Sun J, Mu J, Wang S, Jia C, Li D, Hua H, Cao H. Design and synthesis of chromone-nitrogen mustard derivatives and evaluation of anti-breast cancer activity. *J Enzyme Inhib Med Chem*. 2022; 37(1): 431-444.
3. Waks AG, Winer EP. Breast Cancer Treatment: A Review. *JAMA*. 2019; 321(3): 288-300.
4. Xie Y, Gou Q, Zhang Y, Xie K, Zheng D, Luo C, Suo J, Zhong X, Luo T. Association between age at initial diagnosis and post-metastasis mortality among women with recurrent metastatic breast cancer in China. *BMC Cancer*. 2022; 22(1): 385.
5. Hashim HT, Ramadhan MA, Theban KM, Bchara J, El-Abed-El-Rassoul A, Shah J. Assessment of breast cancer risk among Iraqi women in 2019. *BMC Womens Health*. 2021; 21(1): 412.
6. Abdalzahra RN, Ali RM. Burdens of breast cancer upon women's psychological health at Oncology Hospitals in Baghdad City. *Iraqi J Public Health*. 2017; 1: 15-19.
7. Zuhair A, Khudayir R, Abdulsamad R. Analyze predisposing risk factor of breast cancer (BC) among Iraqi women in Baghdad teaching hospital and oncology unit center in Baghdad. *Baghdad Med J Students*. 2020. 1(1).
8. Al-Hashimi MMY. Trends in Breast Cancer Incidence in Iraq During the Period 2000-2019. *Asian Pac J Cancer Prev*. 2021; 22(12): 3889-3896.

9. Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. *Nature*. 2016; 529(7586): 298-306.
10. Cheng TC, Tu SH, Chen LC, Chen MY, ChenWY, Lin YK, Ho CT, Lin SY, Wu CH, Ho YS. Down-regulation of α -L-fucosidase 1 expression confers inferior survival for triple-negative breast cancer patients by modulating the glycosylation status of the tumor cell surface. *Oncotarget*. 2015; 6(25): 21283-21300.
11. Gan Y, Liang Q, Song X. Diagnostic value of alpha-L-fucosidase for hepatocellular carcinoma: a meta-analysis. *Tumour Biol*. 2014; 35(5): 3953-3960.
12. Yu X, Zhang R, Yang T, Zhang M, Xi K, Lin Y, Wen Y, Wang G, Huang Z, Zhang X, Zhang L. Alpha-l-fucosidase: a novel serum biomarker to predict prognosis in early stage esophageal squamous cell carcinoma. *J Thorac Dis*. 2019; 11(9): 3980-3990.
13. Delacadena M, Fernandez J, Decarlos A, Martinezzorzano V, Gilmartin E, Rodriguezberrocal F. Low levels of alpha-L-fucosidase activity in colorectal cancer are due to decreased amounts of the enzymatic protein and are related with Dukes' stage. *Int J Oncol*. 1996; 9(4): 747-754.
14. El-Houseini ME, El-Sherbiny M, Awad ME, Amer MA, Saad AH, Hussein TD. Serum alpha-L-fucosidase enzyme activity as a marker for hepatocellular carcinoma: comparison with AFP using ROC analysis. *J Egypt Natl Cancer Inst*. 2001; 13(4): 227-283.
15. Berteau O, McCort I, Goasdoué N, Tissot B, Daniel R. Characterization of a new alpha-L-fucosidase isolated from the marine mollusk *Pecten maximus* that catalyzes the hydrolysis of alpha-L-fucose from algal fucoidan (*Ascophyllum nodosum*). *Glycobiology*. 2002; 12(4): 273-282.
16. Li C, Qian J, Lin JS. Purification and characterization of alpha-L-fucosidase from human primary hepatocarcinoma tissue. *World J Gastroenterol*. 2006; 12(23): 3770-3775.
17. Shah M, Telang S, Raval G, Shah P, Patel PS. Serum fucosylation changes in oral cancer and oral precancerous conditions: alpha-L-fucosidase as a marker. *Cancer*. 2008; 113(2): 336-346.
18. Shuang Z, Mao Y, Lin G, Wang J, Huang X, Chen J, Duan F, Li S. Alpha-L-Fucosidase Serves as a Prognostic Indicator for Intrahepatic Cholangiocarcinoma and Inhibits Its Invasion Capacity. *Biomed Res Int*. 2018; 2018: 8182575.
19. Chen D, Xing N, Cui Z, Zhang C, Zhang Z, Li D, Yan L. The Value of Preoperative Alpha-L-Fucosidase Levels in Evaluation of Malignancy and Differential Diagnosis of Urothelial Neoplasms. *J Oncol*. 2020; 2020: 6723616.
20. Otero-Estévez O, Martínez-Fernández M, Vázquez-Iglesias L, Páez de la Cadena M, Rodríguez-Berrocal FJ, Martínez-Zorzano VS. Decreased expression of alpha-L-fucosidase gene FUCA1 in human colorectal tumors. *Int J Mol Sci*. 2013; 14(8): 16986-16998.
21. Zhang SY, Lin BD, Li BR. Evaluation of the diagnostic value of alpha-l-fucosidase, alpha-fetoprotein and thymidine kinase 1 with ROC and logistic regression for hepatocellular carcinoma. *FEBS Open Bio*. 2015; 5: 240-244.
22. Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. *Mol Clin Oncol*. 2013; 1(4): 593-598.
23. Zhu J, Jiang F, Ni HB, Xiao MB, Chen BY, Ni WK, Lu CH, Ni RZ. Combined analysis of serum γ -glutamyl transferase isoenzyme II, α -L-fucosidase and α -fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma. *Exp Ther Med*. 2013; 5(1): 89-94.
24. Khunsook S, Bean BS, McGowan SR, Alhadeff JA. Purification and characterization of plasma membrane-associated human sperm alpha-L-fucosidase. *Biol Reprod*. 2003; 68(3): 709-716.
25. Abdel Hamid NM, Nazmy MH, Moustafa BE, Saad El-din SM. Priority of Alpha-L-Fucosidase Over Alpha fetoprotein in Early Detection of Hepatocellular Carcinoma in Animals and Human. *Acta Oncol Turcica*. 2014: 1-7.
26. Villar E, Calvo P, Cabezas JA. Comparative studies on blood serum alpha-L-fucosidases from several mammalian species. *Comp Biochem Physiol B*. 1978; 60(4): 459-461.
27. DiCioccioRA, Barlow JJ, Matta KL. Substrate specificity and other properties of alpha-L-fucosidase from human serum. *J Biol Chem*. 1982; 257(2): 714-718.
28. Seo HC, Willems PJ, Kretz KA, Martin BM, O'Brien JS. Fucosidosis: four new mutations and a new polymorphism. *Hum Mol Genet*. 1993; 2(4): 423-429.

29. Dong S, Chang Y, Shen J, Xue C, Chen F. Purification, expression and characterization of a novel α -L-fucosidase from a marine bacteria *Wenylingzhuangia fucanilytica*. *Protein Expr Purif*. 2017; 129: 9-17.
30. Fawzy Montaser M, Amin Sakr M, Omar Khalifa M. Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma. *Arab J Gastroenterol*. 2012; 13(1): 9-13.
31. Liu SW, Li YK. Expression, Purification and Characterization of Human α -L-Fucosidase. *J Chin Chem Soc*. 2009; 56(4): 850-858.
32. Huang W, Li X. Significance of fucose expression in lung carcinoma and their brain metastases. *Zhonghua Bing Li Xue Za Zhi*. 2000; 29(4): 259-262.
33. Khunsook S, Alhadeff JA, Bean BS. Purification and characterization of human seminal plasma alpha-L-fucosidase. *Mol Hum Reprod*. 2002; 8(3): 221-227.
34. Hamodat ZMAA. Properties of alpha-L-fucosidase for serum of patients with hepatocellular cancer and cytotoxicity on some cancer cell lines. *Ukr Biochem J*. 2021; 93(6): 76-86.
35. De Ritis F, Coltorti M, Giusti G. An enzymic test for the diagnosis of viral hepatitis; the transaminase serum activities. *Clin Chim Acta*. 1957; 2(1): 70-74.
36. Fukui-Kawaura S, Kawahara T, Araki Y, Nishimura R, Uemura K, Namura K, Mizuno N, Yao M, Uemura H, Ikeda I. A higher De Ritis ratio (AST/ALT) is a risk factor for progression in high-risk non-muscle invasive bladder cancer. *Oncotarget*. 2021; 12(9): 917-922.
37. Ha YS, Kim SW, Chun SY, Chung JW, Choi SH, Lee JN, Kim BS, Kim HT, Yoo ES, Kwon TG, Kim WT, Kim WJ, Kim TH. Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy. *BMC Urol*. 2019; 19(1): 10.
38. Zhang LX, Lv Y, Xu AM, Wang HZ. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. *BMC Cancer*. 2019; 19(1): 841.
39. Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, Eaton JW, Telang S, Chesney J. Targeting aspartate aminotransferase in breast cancer. *Breast Cancer Res*. 2008; 10(5): R84.
40. Lee H, Lee SE, Byun SS, Kim HH, Kwak C, Hong SK. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study. *BJU Int*. 2017; 119(2): 261-267.
41. Gorgel SN, AkinY, Koc EM, Kose O, Ozcan S, Yilmaz Y. Impact of increased aspartate aminotransferase to alanine aminotransferase (De Ritis) ratio in prognosis of testicular cancer. *Investig Clin Urol*. 2019; 60(3): 169-175.
42. Li Y, Fang D, Bao Z, He A, Guan B, He S, Zhan Y, GongY, Li X, Zhou L. High aspartate transaminase/alanine transaminase ratio predicts poor prognosis in patients with localized upper tract urothelial cancer: a propensity score-matched study in a large Chinese center. *Onco Targets Ther*. 2019; 12: 2635-2648.
43. Kang M, Yu J, Sung HH, Jeon HG, Jeong BC, Park SH, Jeon SS, Lee HM, Choi HY, Seo SI. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. *Int J Urol*. 2018; 25(6): 596-603.
44. Yuk HD, Jeong CW, Kwak C, Kim HH, Ku JH. De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study. *Dis Markers*. 2019; 2019: 6702964.
45. Wang K, Guo W, Li N, Shi J, Zhang C, Lau WY, Wu M, Cheng S. Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy: a large-scale, long-term study. *Br J Cancer*. 2014; 110(7): 1811-1819.
46. Alramadhany RW, Hamodat ZMA. Study the level of arginase activity and its correlation with liver and kidney functions for patients with type-2 diabetes in Nineveh governorate. *Egypt J Chem*. 2021; 64(12): 7075-7082.
47. Adhvaryu MR, Reddy N, Vakharia BC. Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach. *World J Gastroenterol*. 2008; 14(30): 4753-4762.

48. Landau S, Everitt BS. A handbook of statistical analyses using SPSS. 2003: Chapman and Hall/CRC, 2003. 366 p.
49. Alramadhany RW, Hamodat ZMA. Study the characteristics of partially purified arginase from the serum of patients with diabetes mellitus type two (DMT2) in the Nineveh Governorate. *Basra J Sci*. 2022; 40(1): 66-82.
50. Mertz S, Benjamin C, Girvalaki C, Cardone A, Gono P, May SG, Comerford E, Than KS, Birch K, Roach M, Myers S, Sasane M, Lavi L, Cameron A, Cardoso F. Progression-free survival and quality of life in metastatic breast cancer: The patient perspective. *Breast*. 2022; 65: 84-90.
51. Ayude D, Páez De La Cadena M, Martínez-Zorzano VS, Fernández-Briera A, Rodríguez-Berrocal FJ. Preoperative serum alpha-L-fucosidase activity as a prognostic marker in colorectal cancer. *Oncology*. 2003; 64(1): 36-45.
52. Teramoto H, Koike M, Tanaka C, Yamada S, Nakayama G, Fujii T, Sugimoto H, Fujiwara M, Suzuki Y, Kodera Y. Tumor budding as a useful prognostic marker in T1-stage squamous cell carcinoma of the esophagus. *J Surg Oncol*. 2013; 108(1): 42-46.
53. Deugnier Y, David V, Brissot P, Mabo P, Delamaire D, Messner M, Bourel M, Legall JY. Serum alpha-L-fucosidase: a new marker for the diagnosis of primary hepatic carcinoma? *Hepatology*. 1984; 4(5): 889-892.
54. Wang H, Fang K, Zhang J, Jiang Y, Wang G, Zhang H, Chen T, Shi X, Li Y, Duan F, Liu J. The significance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients. *Int Urol Nephrol*. 2017; 49(8): 1391-1398.
55. Justus CR, Sanderlin EJ, Yang LV. Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment. *Int J Mol Sci*. 2015; 16(5): 11055-11086.
56. Koppenol WH, Bounds PL. The Warburg effect and metabolic efficiency: re-crunching the numbers. *Science*. 2009; 324(5930): 1029-1033.
57. Rao A, Wiggins C, Lauer RC. Survival outcomes for advanced kidney cancer patients in the era of targeted therapies. *Ann Transl Med*. 2018; 6(9): 165.
58. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. *Proc Natl Acad Sci USA*. 2008; 105(48): 18782-18787.
59. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. *Sci Adv*. 2016; 2(5): e1600200.
60. Ellinger JJ, Lewis IA, Markley JL. Role of aminotransferases in glutamate metabolism of human erythrocytes. *J Biomol NMR*. 2011; 49(3-4): 221-229.
61. Şahin Y, Yılmaz M, Hacıbey İ, Filtekin YC, Çolakerol A, Semerciöz A, Müslümanoğlu AY. Is There Any Correlation Between De Ritis Ratio and Prostate Cancer in Males Who Underwent Transrectal Prostate Biopsy? *Bagcilar Med Bull*. 2021; 6(1): 66-72.